Neonatal sepsis is a bloodstream infection that strikes within the first 28 days of life, and it remains one of the leading causes of death among newborns worldwide. A systematic review and meta-analysis covering 26 studies across 14 countries estimated roughly 2,824 cases per 100,000 live births, with a mortality rate of about 17.6%, though the burden falls disproportionately on low- and middle-income countries.1PubMed Central. Global incidence and mortality of neonatal sepsis: a systematic review and meta-analysis The condition can look deceptively mild in its earliest stages, which is part of what makes it so dangerous: by the time symptoms become obvious, the infection may have already spread to multiple organs.
Early-Onset and Late-Onset Are Different Diseases in Practice
Clinicians split neonatal sepsis into two categories based on timing, and the distinction matters because the germs, the risk factors, and the outcomes differ. Early-onset sepsis occurs within the first three days after birth. Late-onset sepsis begins from day three onward, and it is further divided by whether the baby picked up the infection in the community or in the hospital.2PubMed. Neonatal Sepsis of Early Onset, and Hospital-Acquired and Community-Acquired Late Onset: A Prospective Population-Based Cohort Study Each type affects specific subgroups of newborns and comes with its own set of common pathogens.
In early-onset sepsis, the bacteria usually come from the mother’s birth canal. Group B Streptococcus (GBS) accounts for about 43% of early-onset cases and is the leading cause in full-term infants, while E. coli makes up roughly 29% and dominates among premature babies.3PubMed Central. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues Late-onset sepsis, by contrast, is often caused by organisms that colonize the baby after birth, frequently in the hospital environment. Coagulase-negative staphylococci have become the predominant pathogens in late-onset cases in industrialized countries, responsible for over half of episodes. Gram-negative bacteria like Klebsiella, Enterobacter, and Pseudomonas also play a significant role, particularly in lower-income settings.4Archives of Disease in Childhood – Fetal and Neonatal Edition. Late-onset neonatal sepsis: recent developments
Why Newborns Are So Vulnerable
A full-term, healthy newborn is not defenseless, but the immune system of a neonate operates differently from that of an older child or adult. The innate immune responses that serve as first-line defense differ in capacity, quantity, and quality compared to those of older populations.5PubMed Central. Role of innate host defenses in susceptibility to early-onset neonatal sepsis Adaptive immunity, the part of the immune system that learns to recognize specific threats, is still developing and has had almost no prior exposure to pathogens. Together, these gaps mean that once bacteria enter the bloodstream, the infection can spread and become life-threatening much faster than it would in an older person.
Preterm infants face an even steeper disadvantage. The earlier a baby is born, the less time the immune system has had to mature. Incomplete maturation before a full term of gestation directly increases vulnerability to infection.6PubMed Central. An Immunological Perspective on Neonatal Sepsis At the vascular level, neonatal endothelial cells produce lower amounts of the adhesion molecules needed to recruit immune cells to the site of infection, and they are less effective at neutralizing reactive oxygen species, which means the body’s own inflammatory response can damage tissues more easily.7PubMed Central. Vascular Endothelium in Neonatal Sepsis: Basic Mechanisms and Translational Opportunities This combination of immature defense and fragile tissue makes sepsis in a preterm newborn a genuine emergency.
Recognizing the Signs
One of the most frustrating features of neonatal sepsis for both parents and clinicians is how vague and nonspecific the initial symptoms can be. The infection can present with subtle signs but progress rapidly to organ failure and meningitis.8BMJ. Neonatal sepsis A baby might seem a bit less active, feed poorly, have slight temperature instability, or show mild breathing irregularities. None of those symptoms point specifically to sepsis, and most of them overlap with dozens of other common neonatal issues.
Even in a neonatal intensive care unit where vital signs are monitored continuously, the early changes associated with sepsis are subtle and hard to interpret with standard monitoring tools.9PubMed Central. Heart rate characteristics: physiomarkers for detection of late-onset neonatal sepsis This is a major reason why clinicians often start antibiotics on suspicion alone, well before they have confirmation that an infection is present. Waiting for clear-cut symptoms can mean waiting too long.
The Diagnostic Challenge
The gold standard for confirming sepsis is a blood culture, where a sample of the baby’s blood is placed in a growth medium and monitored for bacteria. The problem is that blood cultures take roughly 48 to 72 hours to return results and have limited sensitivity, meaning they can miss infections entirely.10PubMed Central. Molecular microbiological methods in the diagnosis of neonatal sepsis In the meantime, clinicians must decide whether to treat, and a baby’s condition can deteriorate dramatically during that window.
This gap has driven interest in blood-based biomarkers that can offer faster clues. Two markers are used most widely: C-reactive protein (CRP) and procalcitonin (PCT). Both rise in response to infection, but they perform differently. CRP is cheap and available almost everywhere, yet it tends to rise later and is less sensitive in the earliest stages of infection. PCT rises sooner, correlates with disease severity, and in some studies has shown sensitivity above 85%.11PubMed Central. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review A systematic review comparing the two concluded that PCT has superior early diagnostic potential, though it undergoes a normal physiological rise in healthy newborns during the first couple of days of life, which can complicate interpretation.12PubMed Central. C-reactive Protein Versus Procalcitonin in the Early Diagnosis of Neonatal Sepsis: A Systematic Review
In very low birth weight infants specifically, one study found that both CRP and PCT had similar overall accuracy (both with an area under the curve of 0.83), but CRP was better at confirming a case while PCT was better at ruling one out due to its higher sensitivity and negative predictive value.13Pediatric Research. Comparing procalcitonin and C-reactive protein levels in very low birth weight infants with sepsis When the two are combined, diagnostic accuracy improves further. The meta-analysis of 28 studies found that pairing PCT and CRP yielded pooled sensitivity of about 91%.14PubMed Central. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review Another biomarker called presepsin showed even higher accuracy in pooled analyses, though it is not yet widely available in clinical practice.
Molecular methods, like PCR-based testing that detects bacterial DNA directly in the blood, offer the promise of faster results and higher sensitivity than traditional cultures. However, uncertainty about the bacterial cause of sepsis is not always resolved by PCR results, and the technology still needs refinement before it can reliably replace or supplement blood culture in routine practice.15PubMed Central. Comparison of broad range 16S rDNA PCR and conventional blood culture for diagnosis of sepsis in the newborn: a case control study
Treatment Starts Before You Know the Cause
Because waiting for culture results is risky, the standard approach is to start antibiotics as soon as sepsis is suspected. The most commonly used first-line combination is a beta-lactam antibiotic (usually ampicillin or penicillin) paired with an aminoglycoside (usually gentamicin). Guidelines call for this treatment to begin as soon as possible and always within one hour of the decision to treat.16PubMed Central. Antibiotic regimens for neonatal sepsis – a protocol for a systematic review with meta-analysis Once blood culture results come back, clinicians can narrow the treatment to target the specific organism if one is identified, or stop antibiotics if the cultures remain negative and the baby improves.
This “treat first, confirm later” approach is lifesaving, but it also means a lot of newborns receive antibiotics they may not have needed. That tension sits at the center of neonatal sepsis management. Undertreating a genuine infection can be fatal. Overtreating with antibiotics in an NICU feeds the development of resistant bacteria.
The Growing Problem of Drug-Resistant Infections
Antibiotic resistance is already a serious concern in neonatal intensive care units. Indiscriminate antibiotic use drives the emergence of multidrug-resistant organisms, creating a cycle that threatens public health broadly.17PubMed Central. Fighting Antimicrobial Resistance in Neonatal Intensive Care Units: Rational Use of Antibiotics in Neonatal Sepsis In some settings, the problem is already severe. A study from a tertiary referral hospital in Indonesia found that multidrug-resistant organisms were the cause in over 80% of neonatal sepsis cases. Several factors raised the odds of a resistant infection, including lower birth weight, prolonged rupture of membranes, longer hospital stays, low Apgar scores, and the use of mechanical ventilation.18PubMed Central. Risk factors of multidrug-resistant organisms neonatal sepsis in Surabaya tertiary referral hospital: a single-center study
This is why antibiotic stewardship programs in NICUs, which aim to limit unnecessary antibiotic courses and use the narrowest-spectrum drug that will work, have become increasingly important. The stakes are high: every resistant infection in a fragile newborn narrows the available treatment options and increases the risk of death.
Adjunctive Therapies Have Mostly Disappointed
Researchers have explored several treatments that could be added alongside antibiotics to improve outcomes. Intravenous immunoglobulin (IVIG), which delivers concentrated antibodies, seemed like a logical candidate since newborns have low antibody levels. But a Cochrane review that included the large INIS trial (3,493 infants) found no reduction in mortality during hospital stay, nor in death or major disability at two years of age. The review explicitly recommended against routine IVIG for suspected or proven neonatal infection.19PubMed Central. Intravenous immunoglobulin for suspected or proven infection in neonates
IgM-enriched IVIG fared no better. A network meta-analysis of adjunctive therapies confirmed that IVIG probably does not reduce mortality before discharge. Pentoxifylline, a drug that modifies blood flow and inflammation, showed a possible reduction in hospital stay length (roughly seven fewer days), but the evidence behind that finding was rated very low quality.20PubMed. Adjuvant therapy in neonatal sepsis to prevent mortality – A systematic review and network meta-analysis A separate trial testing pentoxifylline and IgM-enriched IVIG, alone and together, similarly found no reduction in morbidity or mortality.21PubMed. Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis The search for effective add-on therapies continues, but for now, antibiotics remain the only treatment with clear evidence of benefit.
Prevention Strategies That Work
Preventing neonatal sepsis is a more successful story than treating it with anything beyond antibiotics. For early-onset GBS infection specifically, giving the mother antibiotics during labor has made a measurable difference. A large meta-analysis found that implementing any screening-and-treatment strategy cut the risk of early-onset GBS infection by more than half. Universal screening strategies, where all pregnant women are tested and carriers receive antibiotics during labor, outperformed risk-based approaches, which only target mothers with known risk factors like fever or prolonged membrane rupture.22The Lancet. Prevention of Group B streptococcus infections in newborn infants via intrapartum antibiotic prophylaxis based on different strategies: a systematic review and meta-analysis An earlier Cochrane review showed that intrapartum antibiotics for GBS-colonized mothers reduced early neonatal GBS infection by about 83%, though the authors noted high risk of bias in some of the available trials.23Cochrane Database of Systematic Reviews. Intrapartum antibiotics for known maternal Group B streptococcal colonization
Inside the NICU, the most effective and least glamorous prevention measures are hand hygiene and maternal breast milk.24NeoReviews. Prevention of Health Care–Associated Infections in the NICU Breast milk contains immunoglobulins, lactoferrin, and other antimicrobial components that help protect a newborn whose own defenses are still developing.25PubMed Central. Prevention and treatment of neonatal nosocomial infections Probiotics have generated interest as well. In one prospective cohort study of extremely preterm infants, the group receiving probiotics had a significantly lower rate of late-onset sepsis compared to controls (about 47% versus 70%), with increased gut colonization by beneficial Lactobacillus species.26PubMed Central. Effects of Probiotics on Gut Microbiomes of Extremely Preterm Infants in the Neonatal Intensive Care Unit: A Prospective Cohort Study Research into the gut microbiome is starting to explain how this might work mechanistically: preterm infants who go on to develop late-onset sepsis show distinct microbial and metabolic signatures in their stool beforehand, including lower levels of certain fermentation products associated with Bifidobacterium activity in those receiving probiotics.27Cell Reports. Preterm infant gut microbial and metabolic signatures preceding late-onset sepsis and the impact of probiotics
Long-Term Neurodevelopmental Consequences
Surviving neonatal sepsis does not always mean a clean recovery. A systematic review of cognitive and sensory outcomes found that sepsis was consistently linked to poorer neurodevelopment across multiple studies. Preterm infants who experienced sepsis, and especially those who developed meningitis alongside it, had higher rates of significant neurodevelopmental impairment, including lower cognitive scores and higher rates of cerebral palsy. Motor impairments were also common. One study of extremely low birth weight infants found that recurrent late-onset sepsis increased the odds of motor deficits nearly twofold. Another reported that 86% of preterm newborns who survived sepsis showed some form of neurological dysfunction, including abnormalities in muscle tone and reflexes.28PubMed Central. The Impact of Neonatal Sepsis on Long-Term Neurodevelopment: A Systematic Review of Cognitive and Sensory Outcomes
Survivors of invasive GBS disease faced elevated risks of moderate or severe neurodevelopmental impairment that persisted into childhood. Danish and Dutch cohort data showed that the relative risk of cognitive delays was nearly double at ten years of age compared to children who had not experienced neonatal sepsis.29PubMed Central. The Impact of Neonatal Sepsis on Long-Term Neurodevelopment: A Systematic Review of Cognitive and Sensory Outcomes These findings underscore why prevention and rapid treatment are so heavily prioritized. Stopping the infection early does not just save lives; it may protect a developing brain from lasting damage.
Fungal Sepsis in the NICU
Bacteria get the most attention in neonatal sepsis discussions, but fungal infections are a major threat for the smallest, sickest babies. Candida species are a leading cause of serious illness and death in NICUs, with mortality after Candida bloodstream infections reaching as high as 40%. Neurodevelopmental impairment is common among survivors.30PubMed Central. Neonatal fungal infections: when to treat? One of the difficulties with fungal sepsis is that it is extremely hard to diagnose. Cultures grow slowly, and the clinical presentation overlaps with bacterial sepsis. For high-risk, very low birth weight infants who do not improve quickly on antibacterial therapy, clinicians may start empirical antifungal treatment even without culture confirmation. The alternative, waiting for lab proof, carries too high a cost when the infection has a coin-flip mortality rate.
Using Artificial Intelligence for Earlier Detection
Given how subtle early sepsis signs are, researchers have been exploring whether machine learning can detect patterns that human observation misses. A multicenter study developed a deep-learning model that analyzed continuous, noninvasive signals from bedside monitors, including electrocardiogram waveforms and respiratory impedance data. The model identified late-onset sepsis with 83% sensitivity and 73% specificity, and its median early detection was 44 hours before clinical suspicion.31PubMed. Early detection of late-onset neonatal sepsis from noninvasive biosignals using deep learning: A multicenter prospective development and validation study The predictive power came largely from subtle changes in the shape of the heart’s electrical signal and from sudden shifts in breathing patterns, changes that are present in the data but invisible to a nurse scanning a standard monitor display. If technology like this reaches routine clinical use, it could give clinicians a window to intervene earlier, before the infection has time to become overwhelming.
The Economic Toll in Low-Resource Settings
Neonatal sepsis is not just a medical crisis; it is an economic one, especially in the regions where it strikes hardest. In sub-Saharan Africa, where incidence and mortality rates are highest, one analysis estimated that between 5.29 and 8.73 million disability-adjusted life years are lost each year due to neonatal sepsis. The corresponding economic burden, calculated using the value of a statistical life, was projected at anywhere from $10 billion to $469 billion annually.32BMJ Global Health. Economic burden of neonatal sepsis in sub-Saharan Africa That wide range reflects the uncertainty inherent in these estimates, but even the low end represents a staggering cost. Many of the most effective interventions, such as clean delivery practices, hand hygiene, maternal GBS screening, and breast milk feeding, are relatively inexpensive compared to the NICU care and long-term disability management that follows untreated sepsis. The gap between what these interventions cost and what the disease costs is one of the most striking disconnects in global child health.